Benefits
Significantly Increases Muscle Protein Synthesis (MPS)
In a single acute crossover trial (n=10), adding 2 g Velositol to a suboptimal 6 g dose of whey significantly increased the muscle protein synthesis (FSR) response versus whey alone (post-treatment FSR difference p=0.045; the increase from baseline was roughly 60% greater than whey alone, not a literal doubling).
Enhanced Muscle Growth
Increased MPS over time supports greater hypertrophy and lean mass gains with resistance training.
Improved Recovery
Faster MPS rates support faster recovery between training sessions.
Synergistic with Protein
Designed specifically as a co-ingredient with protein supplementation rather than standalone.
Insulinogenic Effect Without Sugar
Modulates insulin response to amplify protein anabolic signaling without requiring carbohydrate addition.
Versatile Protein Source Compatibility
Works with whey, plant proteins, and other protein sources.
Mechanism of action
Insulin Signaling Amplification
Chromium component enhances insulin signaling — insulin is a key anabolic hormone activating MPS pathways including mTOR.
mTOR Pathway Activation
Combined with leucine and other amino acids from protein, Velositol amplifies mTOR (mammalian target of rapamycin) — the master regulator of MPS.
Chromium Glucose Disposal
Improved insulin sensitivity from chromium supports glucose disposal into muscle alongside amino acids.
Protein Utilization Enhancement
Increases efficiency of protein utilization for muscle building rather than oxidation.
Clinical trials
Crossover clinical trial comparing whey protein alone vs whey protein + 2 g Velositol on muscle protein synthesis (MPS).
10 healthy subjects (6 men, 4 women), double-blind crossover design; training status not specified.
Adding 2 g Velositol to 6 g whey significantly increased muscle protein synthesis (FSR) versus whey alone (between-trial FSR p=0.045; WPACr rose from baseline p=0.0004, whey alone was non-significant p=0.23). The FSR increase was ~60% greater than whey alone, not a literal doubling. Critical caveat: small acute crossover trial (n=10, 6 men/4 women); industry-funded (Nutrition 21); measures a short-term surrogate (FSR), not muscle mass or strength; requires larger replication.
No peer-reviewed human Velositol trials on exercise performance or body composition are indexed in PubMed; the only human study is the single acute MPS trial, and additional supportive data come from animal (rat) studies.
Resistance-trained adults.
No published human trials demonstrate Velositol-specific body-composition or performance gains; these outcomes have not been tested in humans and are extrapolated from the single acute MPS study and animal data.